Clinical Genomics

JAX Clinical Genomics integrates the latest sequencing technologies with the insights of an experienced multidisciplinary team of scientists to help clinicians and translational researchers select the best options for personalized care.

JMCRS- C22-cont - Clinical Offerings


JAX MGMT Promoter Methylation Assay

MGMT promoter methylation status is "an essential part of molecular diagnostics for all high-grade gliomas" as stated by NCCN guidelines. The methylation status is a predictor for TMZ treatment in CNS tumors, as well as a prognostic marker.

Learn More
JAX OncoMethyl

JAX OncoMethylTM

The JAX OncoMethyl Array™ utilizes a machine learning algorithm intended to provide supplemental information for the classification of central nervous system (CNS) tumors based on genomic methylation profiling data.

Learn More


Reports on 517 cancer related genes for assessment of all DNA and RNA variant types such as SNVs, CNVs, indels, and fusions, in addition to MSI and TMB.

Learn More
Genetic Drift

Clinical Knowledgebase

JAX-Clinical Knowledgebase (CKB) is a powerful tool for interpreting complex genomic profiles, and represents a valuable resource for clinicians and translational and clinical researchers around the world.

learn more

Clinical Team

Browse profiles of our Clinical Genomics leadership team.  

Learn More

Order now

Download requisition forms to get your tests started today. 

Learn More
  • A collage of some of the scientists and emergency workers JAX has worked with. Press Release December 02, 2020

    JAX nominated as a healthcare hero

    The Hartford Business Journal has recognized JAX among its 2020 Health Care Heroes in the Innovation category, recognizing an organization that has made a positive advancement in medical care or medical science.